N-(3-(3-(5-amino-2-chloro-4-fluoro-3-methylbenzamido)-4-(4-methylpiperazin-1-yl)phenyl)prop-2-yn-1-yl)tetrahydro-2H-pyran-4-carboxamide

ID: ALA4857312

PubChem CID: 164616338

Max Phase: Preclinical

Molecular Formula: C28H33ClFN5O3

Molecular Weight: 542.06

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: Cc1c(F)c(N)cc(C(=O)Nc2cc(C#CCNC(=O)C3CCOCC3)ccc2N2CCN(C)CC2)c1Cl

Standard InChI: InChI=1S/C28H33ClFN5O3/c1-18-25(29)21(17-22(31)26(18)30)28(37)33-23-16-19(5-6-24(23)35-12-10-34(2)11-13-35)4-3-9-32-27(36)20-7-14-38-15-8-20/h5-6,16-17,20H,7-15,31H2,1-2H3,(H,32,36)(H,33,37)

Standard InChI Key: DQKAXADDLDHJAJ-UHFFFAOYSA-N

Molfile:

 
     RDKit          2D

 38 41  0  0  0  0  0  0  0  0999 V2000
    8.7494   -3.3035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4595   -3.7220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4519   -4.5471    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7301   -4.9535    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0202   -4.5350    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0277   -3.7100    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.1619   -4.9655    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.8794   -4.5591    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.1543   -5.7905    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.4367   -6.1970    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4291   -7.0220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4174   -7.8470    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4098   -8.6720    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1239   -9.0906    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1163   -9.9155    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3947  -10.3220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6846   -9.9035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6923   -9.0786    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3871  -11.1471    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.0971  -11.5656    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.0895  -12.3905    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3720  -12.7970    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.6619  -12.3785    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.6695  -11.5536    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3643  -13.6221    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5440   -9.9317    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.2539  -10.3502    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.9715   -9.9437    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6815  -10.3622    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.6740  -11.1873    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.9563  -11.5937    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.2464  -11.1752    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5515   -9.1067    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.8264  -10.3382    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.4032   -9.9557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.3881  -11.6057    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   12.9791   -9.1187    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
   12.9488  -12.4187    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  5  6  1  0
  1  6  1  0
  7  8  2  0
  7  9  1  0
  3  7  1  0
 10 11  1  0
 11 12  3  0
 13 14  1  0
 14 15  2  0
 15 16  1  0
 16 17  2  0
 17 18  1  0
 13 18  2  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 19 24  1  0
 22 25  1  0
 16 19  1  0
 26 27  1  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  2  0
 31 32  1  0
 27 32  2  0
 26 33  2  0
 26 34  1  0
 29 35  1  0
 30 36  1  0
 28 37  1  0
 31 38  1  0
 15 34  1  0
 12 13  1  0
  9 10  1  0
M  END

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Unknown	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 542.06	Molecular Weight (Monoisotopic): 541.2256	AlogP: 3.27	#Rotatable Bonds: 5
Polar Surface Area: 99.93	Molecular Species: NEUTRAL	HBA: 6	HBD: 3
#RO5 Violations: 1	HBA (Lipinski): 8	HBD (Lipinski): 4	#RO5 Violations (Lipinski): 1
CX Acidic pKa: 12.69	CX Basic pKa: 7.60	CX LogP: 3.29	CX LogD: 2.88
Aromatic Rings: 2	Heavy Atoms: 38	QED Weighted: 0.40	Np Likeness Score: -1.42

References

1. Chen W, Chen X, Li D, Wang X, Long G, Jiang Z, You Q, Guo X.. (2021) Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity., 223 [PMID:34225179] [10.1016/j.ejmech.2021.113677]
2. Karatas, Hacer H, Townsend, Elizabeth C EC, Bernard, Denzil D, Dou, Yali Y and Wang, Shaomeng S. 2010-07-22 Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. [PMID:20575550]
3. Bolshan, Yuri Y and 16 more authors. 2013-03-14 Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction. [PMID:24900672]
4. Getlik, Matthäus M and 17 more authors. 2016-03-24 Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). [PMID:26958703]
5. Li, Dong-Dong DD and 9 more authors. 2016-08-08 Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5. [PMID:27116709]
6. Li, Dong-Dong DD and 8 more authors. 2016-11-29 High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity. [PMID:27598236]
7. Li, Dong-Dong DD and 5 more authors. 2016-11-15 Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction. [PMID:27720555]
8. Wang, Feng F and 17 more authors. 2018-07-12 Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design. [PMID:29889518]
9. Ye, Xiaoqing X and 11 more authors. 2019-02-15 The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening. [PMID:30626558]
10. Tian, Jianhua and 24 more authors. 2020-01-23 Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core. [PMID:31858797]
11. Chacón Simon, Selena and 14 more authors. 2020-04-23 Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design. [PMID:32223236]

N-(3-(3-(5-amino-2-chloro-4-fluoro-3-methylbenzamido)-4-(4-methylpiperazin-1-yl)phenyl)prop-2-yn-1-yl)tetrahydro-2H-pyran-4-carboxamide

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source